UK Markets closed

ObsEva SA (OBSV)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.7700+0.1000 (+5.99%)
At close: 04:00PM EDT
1.7700 0.00 (0.00%)
After hours: 07:56PM EDT
Sign in to post a message.
  • L
    Did anyone have an opportunity to see the corporate update at the HC Wainwright conference in Miami today? According to the presentation, the reason for the partnership with Theramex to support commercialization outside of US, Canada, and Asia is so they can concentrate all their efforts on the US (“where most of the economics are”) through their relationship with Syneos and their dedicated to OBSV sales force. There was also confirmation that they will be updating their endometriosis dose for uterine fibroids to bring it in line with the 100mg for fibroids, as even though they failed to meet their endpoints in the January trials, they are now confident in their level of efficacy at raised levels. No timeline given for this. Most importantly they emphasized they are “constantly looking for additional [licensing] agreements and relationships to further build value for our shareholders,” and “well-positioned to fund the company going forward.” The CFO, unfortunately, had the charisma of a wet blade of grass.
  • L
    “We believe that current market conditions present opportunities within the sector and that we are strongly positioned to be a catalyst for any roll up merger or acquisition, partnership or licensing opportunities that may present as we look to enhance our value and fully realize the potential that exists within the sector.“ Brian at the Q1 conference call.
  • g
    hope this means the board is searching for a buyer. Any thoughts on what premium to today's sp a buyer would pay for this company? See from announcement of new Board Chair:
    "Ms. Clancy has over 30 years’ experience in the pharmaceutical industry, including fifteen years in business development at GlaxoSmithKline (GSK) where she was most recently Head of Transactions and Alliance Management, responsible for innovative deals ranging from early drug discovery partnerships to global commercial alliances, and mergers and acquisitions."
  • P
    if approved in Europe, does it mean it will be approved in US as well?
    If approved in Europe only, would it be still a takeover target?
  • A
    All these quick drops then recoveries are odd.
  • s
    Very low volume today something is brewing
  • G
    Have u guys read corporate update?
    It simple word it means JGB can dilute our share just in case if it tries to go up.
    We are doomed. I hope share does not go above 3 before august 23rd the 4th Tranche
  • D
    it says shareholders approved but stock tanked almost 9 percent from ath today
  • A
    I would really like to see $2. It’s been far too long.
  • C
    As per past Obseva conferences, I had a good impression about Elizabeth Garner. It is unfortunate that she is leaving us. Well, as Obseva pipeline is maturing, and Ebopiprant and Nolasiban being developed by Obseva partners, maybe this move makes sense.
  • I
    Europe decision can come any day in the meantime expect a run-up into that date, this is a bing deal for the company, unmet need and first drug, this will be a huge money spinner.
  • C
    Shareholder voting for ObsEva's annual meeting ends in a little over 8 days. Please remember to vote if you haven't. Voting is the only real way we have to communicate our sentiment with mgmt's decisions over the past few years since the IR department doesn't return emails...
  • L
    At the Conference Call they basically said that based on the actual evaluation they will be acquired following the FDA approval. Stay long.
  • C
    Holding with such a low volume in uncertain economic times. NBI is down 2%, XBI is down 3.5%. Does it mean buyout is around the corner and therefore Obseva stopped their dilutive action ?
  • O
    Keep in adding
  • L
    ObsEva to present ‘corporate update’ at HC Wainwright Conference in Florida on Tues, May 23rd. Timing is very interesting, considering they also said they’d have a business ‘announcement’ with earnings report. Will be keen to see what they say.
    pressrelease detail - ObsEva
  • L
    While I’m not thrilled that a 15m max compensation package (about 10% of the market cap) for the board passed at this share price, it is worth noting that it’s for the fiscal year 2023, which we’re a year away from beginning.

    My cautious hope is that the board believes the value of the company will multiply several fold by that point, justifying the sticker shock. While they’ve clearly been a bit greedy, you don’t kill the entire hive if you want to keep getting honey, which 15m would do at current numbers.
  • L
    ‘Any resolution(s) you don't vote for will be voted according to The Board of Directors's recommendation if it provides one.‘

    If you do not vote, the board WILL use YOUR VOTE to dilute and pay themselves in excess of 15million. It is NOT an abstaining vote. This is from their voter form.

    I am not against board compensation as a rule but at this stock price it is unacceptable.